Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269726 | 1.00 | SMYD3 (0.36) | SMYD3LMNAGAAF2ST14 | |
| SCHEMBL14289080 | 0.91 | — | — | |
| SCHEMBL4336160 | 0.81 | LMNA (0.52) | LMNAGAA | |
| SCHEMBL23153441 | 0.80 | SMYD3 (0.39) | SMYD3F2ST14PRSS1PRSS2 | |
| SCHEMBL20445357 | 0.80 | SMYD3 (0.39) | SMYD3F2ST14PRSS1PRSS2 | |
| SCHEMBL10590700 | 0.79 | LMNA (0.56) | LMNAGAA | |
| Iodide SCHEMBL11299060 | 0.77 | LMNA (0.54) | LMNAGAA | |
| SCHEMBL4810782 | 0.76 | ST14 (0.39) | SMYD3F2ST14PRSS1PRSS2 | |
| SCHEMBL4810786 | 0.76 | ST14 (0.39) | SMYD3F2ST14PRSS1PRSS2 | |
| SCHEMBL13932387 | 0.75 | LMNA (0.31) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485632-B2 | Cephalosporins | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-02-03 | — | — | US | disclosed |
| US-7485632-B2 | Cephalosporins | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-02-03 | — | — | US | disclosed |
| EP-1529050-B1 | CEPHALOSPORINS | SANDOZ AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | NABRIVA THERAPEUTICS AG (AT) | 2005-10-20 | — | — | US | disclosed |
| EP-1529050-A1 | CEPHALOSPORINS | Sandoz AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004007505-A1 | CEPHALOSPORINS | SANDOZ AG (CH) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234233-A1 | e.g. 3-{(E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl}-7- {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid; microbiocide; Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas | CD14, GNE, ECH1 | SMYD3 531/4885LMNA 4346/4885GAA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.